Literature DB >> 2201262

Haemolytic uraemic syndromes in the British Isles, 1985-8: association with verocytotoxin producing Escherichia coli. Part 2: Microbiological aspects.

H Kleanthous1, H R Smith, S M Scotland, R J Gross, B Rowe, C M Taylor, D V Milford.   

Abstract

In a three year study of children under 16 years with haemolytic uraemic syndrome faecal samples were examined for the presence of Verocytotoxin producing Escherichia coli (VTEC) using DNA probes and for free neutralisable Verocytotoxin in a Vero cell assay with specific antisera. There was evidence of VTEC infection in 58 of 185 (31%) samples. A total of 53 VTEC was identified from patients with haemolytic uraemic syndrome. Thirty eight VTEC belonged to serotype O157:H7 or O157:H-, 34 produced VT2 only, and four strains produced both VT1 and VT2. The remaining 15 VTEC belonged to nine different O serogroups; three strains produced VT1, 10 produced VT2, and two were positive for VT1 and VT2. Three control groups of patients without haemolytic uraemic syndrome were also examined. There was evidence of VTEC infection in 8%, 6%, and 4% of specimens from individuals with bloody diarrhoea, those with diarrhoea only, and healthy controls respectively. VTEC from the bloody diarrhoeal and diarrhoeal controls were O157:H7 but those from the healty controls could not be O serogrouped. This study confirms the association of VTEC, and particularly strains of O157:H7, with haemolytic uraemic syndrome. Strains producing VT1, VT2, or both toxins were isolated, although over 94% of VTEC produced VT2 alone or together with VT1.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2201262      PMCID: PMC1792459          DOI: 10.1136/adc.65.7.722

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  31 in total

1.  Phage-typing scheme for Escherichia coli O157:H7.

Authors:  R Ahmed; C Bopp; A Borczyk; S Kasatiya
Journal:  J Infect Dis       Date:  1987-04       Impact factor: 5.226

Review 2.  The epidemiologic, clinical, and microbiologic features of hemorrhagic colitis.

Authors:  L W Riley
Journal:  Annu Rev Microbiol       Date:  1987       Impact factor: 15.500

3.  Isolation of Escherichia coli O157:H7 from retail fresh meats and poultry.

Authors:  M P Doyle; J L Schoeni
Journal:  Appl Environ Microbiol       Date:  1987-10       Impact factor: 4.792

4.  Properties of strains of Escherichia coli belonging to serogroup O157 with special reference to production of Vero cytotoxins VT1 and VT2.

Authors:  S M Scotland; G A Willshaw; H R Smith; B Rowe
Journal:  Epidemiol Infect       Date:  1987-12       Impact factor: 2.451

5.  Haemolytic uraemic syndromes in the British Isles 1985-8: association with verocytotoxin producing Escherichia coli. Part 1: Clinical and epidemiological aspects.

Authors:  D V Milford; C M Taylor; B Guttridge; S M Hall; B Rowe; H Kleanthous
Journal:  Arch Dis Child       Date:  1990-07       Impact factor: 3.791

6.  Cloning of genes determining the production of vero cytotoxin by Escherichia coli.

Authors:  G A Willshaw; H R Smith; S M Scotland; B Rowe
Journal:  J Gen Microbiol       Date:  1985-11

7.  Hemolytic uremic syndrome and diarrhea associated with Escherichia coli O157:H7 in a day care center.

Authors:  J S Spika; J E Parsons; D Nordenberg; J G Wells; R A Gunn; P A Blake
Journal:  J Pediatr       Date:  1986-08       Impact factor: 4.406

8.  Heterogeneity of Escherichia coli phages encoding Vero cytotoxins: comparison of cloned sequences determining VT1 and VT2 and development of specific gene probes.

Authors:  G A Willshaw; H R Smith; S M Scotland; A M Field; B Rowe
Journal:  J Gen Microbiol       Date:  1987-05

9.  Haemorrhagic colitis and Vero-cytotoxin-producing Escherichia coli in England and Wales.

Authors:  H R Smith; B Rowe; R J Gross; N K Fry; S M Scotland
Journal:  Lancet       Date:  1987-05-09       Impact factor: 79.321

10.  Escherichia coli O157:H7 as the predominant pathogen associated with the hemolytic uremic syndrome: a prospective study in the Pacific Northwest.

Authors:  M A Neill; P I Tarr; C R Clausen; D L Christie; R O Hickman
Journal:  Pediatrics       Date:  1987-07       Impact factor: 7.124

View more
  76 in total

1.  Haemolytic uraemic syndrome and E coli O157.

Authors:  M Fitzpatrick
Journal:  BMJ       Date:  1999-03-13

2.  Virulence factors and phenotypical traits of verotoxin-producing Escherichia coli strains isolated from asymptomatic human carriers.

Authors:  R Stephan; F Untermann
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

3.  Serum amyloid P component binding to Shiga toxin 2 requires both a subunit and B pentamer.

Authors:  Paola Marcato; Kathleen Vander Helm; George L Mulvey; Glen D Armstrong
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

4.  Impaired detection of faecal verocytotoxin in the presence of Clostridium difficile cytotoxin in patients with haemolytic uraemic syndrome.

Authors:  I Luzzi; F Minelli; A Gianviti; A Caprioli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-10       Impact factor: 3.267

5.  Escherichia coli O157:H7, other verotoxin-producing E coli and the hemolytic uremic syndrome in childhood.

Authors:  P C Rowe
Journal:  Can J Infect Dis       Date:  1995-03

6.  Multiplex PCR for direct detection of Shiga toxigenic Escherichia coli strains producing the novel subtilase cytotoxin.

Authors:  Adrienne W Paton; James C Paton
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

7.  Protective immunization of mice with an active-site mutant of subtilase cytotoxin of Shiga toxin-producing Escherichia coli.

Authors:  Ursula M Talbot; James C Paton; Adrienne W Paton
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

Review 8.  Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

Authors:  Saul Tzipori; Abhineet Sheoran; Donna Akiyoshi; Arthur Donohue-Rolfe; Howard Trachtman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

9.  Direct evidence of neuron impairment by oral infection with verotoxin-producing Escherichia coli O157:H- in mitomycin-treated mice.

Authors:  J Fujii; T Kita; S Yoshida; T Takeda; H Kobayashi; N Tanaka; K Ohsato; Y Mizuguchi
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

10.  Characterization of verocytotoxin-producing Escherichia coli O157 isolates from patients with haemolytic uraemic syndrome in Western Europe.

Authors:  A E Heuvelink; N C van de Kar; J F Meis; L A Monnens; W J Melchers
Journal:  Epidemiol Infect       Date:  1995-08       Impact factor: 2.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.